A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 9/00 (2006.01) A61K 9/48 (2006.01) A61K 31/5377 (2006.01) A61K 47/00 (2006.01) A61K 47/02 (2006.01) A61K 47/14 (2006.01) A61K 47/20 (2006.01)
Patent
CA 2758596
An orally deliverable pharmaceutical composition comprises a Bcl-2 family protein inhibitory compound, e.g., ABT-263, a heavier-chalcogen antioxidant and a substantially non-aqueous lipid carrier, wherein said compound and said antioxidant are in solution in the carrier. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
L'invention porte sur une composition pharmaceutique administrable par voie orale qui comprend un composé inhibiteur de protéine de la famille Bcl-2, par exemple ABT-263, un anti-oxydant chalcogène plus lourd et un support lipidique sensiblement non aqueux, ledit composé et ledit anti-oxydant étant en solution dans le support. La composition est appropriée pour une administration orale à un sujet en ayant besoin pour le traitement d'une maladie caractérisée par la surexpression d'une ou plusieurs protéines anti-apoptotiques de la famille Bcl-2, par exemple le cancer.
Catron Nathaniel
Fickes Michael
Fischer Cristina
Haight Anthony R.
Heemstra Katherine
Abbott Laboratories
Torys Llp
LandOfFree
Stabilized lipid formulation of apoptosis promoter does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stabilized lipid formulation of apoptosis promoter, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stabilized lipid formulation of apoptosis promoter will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2089152